変異とecDNAの相互作用が泌尿器がんの進化を形作る

Duy D Nguyen¹, William F Hooper², Weisi Liu¹

¹Department of Medicine, Weill Cornell Medicine, New York, NY, USA.

Nature

|October 9, 2024

まとめ

ゲノム解析は,化学療法とAPOBEC3が,クロモソーム外DNA (ecDNA) の形成を通じて泌尿器がんの進化を促し,治療への耐性および腫瘍の複雑化につながることを明らかにしています.

科学分野:

ゲノミクス
癌生物学
分子腫瘍学

背景:

先進的な尿管がんは遺伝的多様性を持つ致命的な病気です
ゲノム進化と変異性の過程を理解することは効果的な治療に不可欠です

研究の目的:

泌尿器がんにおけるゲノムシグネチャーの進化を調査する
変異性プロセスと構造変異 (SV) の相互作用を分析する.
癌の進行と治療抵抗における染色体外DNA (ecDNA) の役割を理解する.

主な方法:

連続腫瘍のサンプルを突入した変異シグネチャーと遺伝分析
構造変異 (SV) を分析するためのゲノムグラフ計算ツール.
ロングリード全ゲノムシーケンシング (オックスフォード・ナノポール・テクノロジーズ) とデノボアセンブリ.
CCND1 ecDNAの実験モデリング

主要な成果:

APOBEC3によって引き起こされる変異は早期に発生し,クローン化であり,化学療法によって後期に発生するサブクローナル変異が引き起こされる.
高複製数の円形アンプリカン (ecDNA形成SV) が頻繁に観察されました.
エクDNA内のAPOBEC3と化学療法変異の明確な時間的なパターンが特徴付けられました.
ほとんどのCCND1増幅は,円形のecDNA形成SVの中で発生する.
エクDNA形成性SVは,治療抵抗性およびがんの進化に寄与する.

結論:

泌尿器がんの進化を促す基本的なメカニズムを特定した.
腫瘍の進行と治療抵抗に重要な役割を果たします.
この発見は,進行した泌尿器がんの治療に重要な意味を持つ.

さらに関連する動画

09:16

Ex Vivo Organoid Model of Adenovirus-Cre Mediated Gene Deletions in Mouse Urothelial Cells

Published on: May 5, 2022

2.6K

06:38

Novel Method of Plasmid DNA Delivery to Mouse Bladder Urothelium by Electroporation

Published on: May 3, 2018

8.5K

関連する概念動画

Mutations

Nucleotide Excision Repair

3.5K

DNA Distortion and Damage
Cells are regularly exposed to mutagens—factors in the environment that can damage DNA and generate mutations. UV radiation is one of the most common mutagens and is estimated to introduce a significant number of changes in DNA. These include bends or kinks in the structure, which can block DNA replication or transcription. If these errors are not fixed, the damage can cause mutations, which in turn can result in cancer or disease depending on which sequences are...

3.5K

01:25

Mutagenicity and Carcinogenicity

1.2K

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...

1.2K

01:20

Mismatch Repair

4.8K

Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...

4.8K

02:21

Cancers Originate from Somatic Mutations in a Single Cell

11.8K

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...

11.8K

01:16

In-vitro Mutagenesis

13.8K

To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.